Misonix purchase patents from ProRhythm

Misonix, Inc. has announced that it has purchased three patents associated with High Intensity Focused Ultrasound ("HIFU") technology from ProRhythm, Inc.

The patents relate to HIFU transducer arrays method of fabrication, ultrasonic lenses, and an intrabody HIFU applicator. The purchase also includes prototypes, transducers and equipment.

Michael A. McManus, Jr., President and CEO said, "We believe the purchase of this patented technology will enable us to continue the internal development of our own HIFU transducer applications. We believe the covered technology will be useful in developing smaller transducers, which may be reusable or disposable. Additionally, we intend to develop the technology for use in a variety of tissue applications. The use of ultrasound is ideal for minimally invasive applications and the technology may provide us entry into other large and growing markets."

Mr. McManus continued, "We presently have a worldwide license from Focus Surgery, Inc., for kidney, liver and breast applications using HIFU. Our plan going forward will involve the development of our own proprietary HIFU technology. We are presently distributing the Sonablate(R)500 in Europe, which uses HIFU for the treatment of prostate cancer. In addition, we are continuing our clinical studies using HIFU for the minimally invasive treatment of kidney tumors. We believe this technology acquisition will further enhance our industry leading position in the development and use of multiple products using HIFU for the treatment of tumors."